Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Janssen halts trials of FAAH inhibitor

January 21, 2016 1:51 AM UTC

The Janssen Research & Development LLC unit of Johnson & Johnson suspended dosing of fatty acid amide hydrolase ( FAAH) inhibitor JNJ-42165279 in two Phase II trials. The decision follows the death of a healthy volunteer who received a different company's FAAH inhibitor in a French Phase I trial.

Janssen spokesperson Greg Panico told BioCentury about 120 patients have been treated to date with JNJ-42165279, and said Janssen has not received any reports of serious adverse events. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article